INTRODUCTION AND OBJECTIVES: An accurate assessment of renal function is mandatory in the majority or urological and oncological patients to prevent renal impairment and cancer nonrelated deaths. Nowadays, the large part of clinicians apply CKD-EPI/MDRD formulas or 24h creatinine clearance to determine the glomerular filtration rate (GFR) before and after renal surgery (for cancer, donation, stones and pyelouretheral junction stenosis) and in metastatic patients for establish the right oncological treatment. Unfortunately, estimated GFR (eGFR) displays a wide error in reflecting real kidney function with measured GFR (mGFR) and this may lead to important consequences in the correct evaluation of patients.
METHODS: A retrospective and prospective study based on 200 pts composed by 150 pts with uro-oncological cancer or renal functional diseases (UOCRD) and 50 kidney donors (KD) was performed in two different centers to compare eGFR formula with renal scintigraphy (N¼150) or iohexol clearance (N¼50). The agreement between eGFR and mGFR was evaluated using total deviation index (TDI) and concordance correlation coefficient (CCC).
RESULTS: The agreement between formulas and mGFR was poor. The TDI for MDRD was 83% and for CKD-EPI was 76%, indicating that 90% of the estimations for both formulas were included within a margin of error from mGFR of about AE 76 to 80%. CCC for MDRD was 0.74 and for CKD-EPI was 0.78, indicating poor concordance between eGFR and mGFR. UOCRD population, using eGFR formulas (CKD-EPI/MDRD), was composed by 28%-21% of CKD stage I pts (eGFR > 90 ml/min), 38 %-41% CKD stage II, 7%-13% CKD stage IIIa, 16%-15% CKD stage IIIb, 9%-8% CKD stage IV, 2%-2% CKD stage V. Using Renal Scintigraphy measurements, we revealed these different proportions: 37% CKD I, 26% CKD II, 17% CKD IIIa, 15 % CKD IIIb, 9% CKD IV, 0% CKD V. Moreover, the discrepancy between mGFR with renal scintigraphy and eGFR with formulas was of 57% in CKD I, 23% in CKD II, 72% in CKD IIIa, 47% in CKD IIIb, 50% in CKD IV, 100% in CKD V stage. KD population presented eGFR > 90 ml/min with formulas for each pts; after iohexol measurement, 5 patients displayed mGFR lower than 70 ml/min CONCLUSIONS: CKD-EPI and MDRD formulas may over or underestimate mGFR in more than 50% of pts, generating false evaluations in the clinical management and drug therapies for oncological, urological and kidney donor patients. We suggest to use a gold standard technique of mGFR (eg renal scintigraphy, iohexol measurement) in selected cases when GFR is crucial to determine the surgical/therapeutic approach.
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Shay Golan*, Chicago, IL; Paz Lotan, Shlomi Tapiero, Jack Baniel, Andrei Nadu, Ofer Yossepowitch, Petach Tikva, Israel INTRODUCTION AND OBJECTIVES: The utility of renal mass biopsies (RMB) in the diagnosis and management of kidney tumors remains debatable. We assessed the patients and urologists preferences in this regard.
METHODS: Seventy-three patients diagnosed with renal tumors and 59 board-certified urologists were asked to participate in an interview-based study. Decision analysis was quantified using the standard gamble method to determine the minimal accepted accuracy (MAA) at which RMB would be favored as part of the diagnostic process. Clinical and demographic data with potential to affect participants preferences were analyzed.
RESULTS: At the time of study interview, 56 patients (77%) were referred for kidney surgery and 17 (23%) opted for surveillance. Overall, 59% of the patients were willing to accept some level of inaccuracy (1-20%), whereas 41% would refute a biopsy irrespective of their designated treatment. Anxiety associated with the possibility of missing cancer was the primary determinant (70%) for declining RMB among Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e259
